Gilead (GILD) Secures EU Approval for Breast Cancer Drug Trodelvy

Gilead Sciences (GILD) announced June 23, 2026, that the European Commission granted marketing authorization for its drug Trodelvy. The approval targets adult patients with unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer who have received prior endocrine-based therapy and at least two additional systemic therapies. This expands Trodelvy's market reach within the EU for a significant patient population. This European approval follows similar authorizations in the U.S., Great Britain, Canada, and Switzerland for the same indication. Trodelvy, also known as sacituzumab govitecan, is an antibody-drug conjugate. Its efficacy was demonstrated in the Phase 3 TROPiCS-02 study, which showed a statistically significant and clinically meaningful overall survival and progression-free survival benefit compared to chemotherapy.